European Commission says recast consultation confirms need for legislative improvements
This article was originally published in SRA
The European Commission believes that its consultation on a possible recast of the medical device directives has confirmed the need for legislative changes in the medtech regulatory framework, but it agrees with industry stakeholders that more time is needed to draft formal proposals1-3. Formal proposals are unlikely to emerge this year.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.